The holo beta-lactoglobulin lozenge reduces symptoms in cat allergy-Evaluation in an allergen exposure chamber and by titrated nasal allergen challenge.

"CONFLICT OF INTEREST STATEMENT Franziska Roth‐Walter and Erika Jensen‐Jarolim declare inventorship of the patent EP 14150965.3, Year: 01/2014; US 14/204,570 (Method and means for diagnosing and treating allergy; owned by Biomedical International R + D GmbH, Vienna, Austria), underlying the immunoBON® lozenge. Erika Jensen‐Jarolim is a shareholder of Biomedical Int. R + D GmbH, Vienna, Austria and collaborates with Bencard Allergie GmbH in projects and studies on holoBLG. Franziska Roth‐Walter received research funding from Biomedical International R + D GmbH, Vienna, Austria and lecture honoraria by Bencard Allergie GmbH, Munich, Germany and Vienna, Austria, and Allergy Therapeutics, Worthing, UK. Jennifer Raab, Anke Graessel, Thomas Zwingers and Matthias F. Kramer are employees of Allergy Therapeutics/Bencard Allergie GmbH. Karl–Christian Bergmann received honoraria for lectures from ALK, AstraZeneca, Bencard, GSK, HAL, LETI Novartis, Sanofi during last 2 years, works for the German Pollen Information Service Foundation and is member of ECARF‐Institute GmbH. Torsten Zuberbier reports lecture honoraria from AstraZeneca, ALK, AbbVie, Almirall, Astellas, Bayer health Care, Bencard, Berlin Chemie, FAES, HAL, Leti, Meda, menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes, Takeda, Teva, UCB, Henkel, Kryolan and LÓreal. Sylvia Becker and Sebastian Kugler report no competing interests."

"In memory of our dear colleague and co‐author, Thomas Zwingers, who passed away unexpectedly. Thomas' statistical analyses were a great contribution to the current work. His expertise, dedication and down‐to‐earth nature will be missed dearly. The study was funded by Bencard Allergie GmbH, Germany. The holoBLG lozenges were provided by Biomedical International R+D GmbH, Vienna, Austria. The authors thank Alan Bullimore for proofreading the manuscript."